Stoke Therapeutics (NASDAQ:STOK) Given New $38.00 Price Target at Wedbush

Stoke Therapeutics (NASDAQ:STOK) had its target price upped by Wedbush from $36.00 to $38.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages also recently weighed in on STOK. Needham & Company LLC boosted their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wolfe Research began coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, UBS Group set a $50.00 target price on Stoke Therapeutics in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $39.83.

Stoke Therapeutics Price Performance

STOK opened at $32.87 on Tuesday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The firm has a market capitalization of $1.88 billion, a P/E ratio of 49.06 and a beta of 1.07. The company’s 50-day moving average is $32.69 and its 200 day moving average is $29.89.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $5.32 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, equities research analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the sale, the director owned 283,302 shares in the company, valued at $11,258,421.48. This represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the transaction, the insider owned 31,339 shares of the company’s stock, valued at approximately $1,253,560. This trade represents a 12.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 38,203 shares of company stock valued at $1,517,541 in the last quarter. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC increased its stake in Stoke Therapeutics by 333.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after acquiring an additional 1,116,452 shares during the last quarter. State Street Corp lifted its stake in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after purchasing an additional 1,072,176 shares during the last quarter. Corient Private Wealth LLC bought a new stake in Stoke Therapeutics during the second quarter worth about $7,489,000. BVF Inc. IL boosted its holdings in shares of Stoke Therapeutics by 36.7% in the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after purchasing an additional 608,578 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after purchasing an additional 600,687 shares during the last quarter.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Analysts raised targets and ratings — Needham raised its price target from $35 to $40 and maintains a “buy” rating; Wedbush raised its target from $36 to $38 and keeps an “outperform” rating, signaling continued analyst confidence and potential upside. Analyst Price Target Raises
• Neutral Sentiment: Company granted inducement stock options (58,650 options to six new hires effective March 16, 2026) — this helps recruit talent but adds potential future dilution. Inducement Grants Release
• Negative Sentiment: Quarterly results missed expectations — EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.32M expected. The revenue shortfall and wider EPS miss are the clearest drivers of downward pressure on the share price. Quarterly Earnings Report
• Negative Sentiment: Insider sale — Director Arthur A. Levin sold 605 shares at an average $36.80, reducing his holdings by ~12.5%. The sale is relatively small in dollar terms but may be interpreted negatively by some investors. SEC Form 4

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.